Paper Details

  1. Home
  2. Paper Details

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

Author: Brown-FrandsenKirstine, ColhounHelen M, DeanfieldJohn, EmersonScott S, GronningMarianne O L, HolstAnders Gaarsdal, HovinghG Kees, KahnSteven E, KushnerRobert F, LincoffA Michael, LingvayIldiko, MarsoSteve, PlutzkyJorge, RavnHenrik, RyanDonna H

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The SELECT trial is evaluating the efficacy of semaglutide 2.4 mg subcutaneously once weekly in preventing major adverse cardiovascular events in patients with established CVD and overweight or obesity but without diabetes. This is the first cardiovascular outcomes trial to evaluate the superiority in major adverse cardiovascular events reduction for an antiobesity medication in such a population.
Paper Details　
Original Abstract of the Article :
Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has been widely appreciated that obesity is a major risk factor for CVD, treatments that produce effective, durable weight loss and the impact of weight reduction in reducing cardiovascular risk have been elusive. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ahj.2020.07.008

データ提供：米国国立医学図書館（NLM）

Semaglutide: A Promising New Approach to Cardiovascular Health in Obesity

The field of [Cardiovascular Disease (CVD)] is constantly seeking new approaches to address the rising burden of obesity and its associated cardiovascular risks. This study introduces the [SELECT Trial], a large-scale clinical trial investigating the cardiovascular benefits of [Semaglutide], a [GLP-1 Receptor Agonist (RA)], in individuals with [Overweight or Obesity] and established [CVD]. The trial aims to assess the potential of [Semaglutide] in preventing major adverse cardiovascular events, providing valuable insights into its role in cardiovascular health management.

The SELECT Trial: A Beacon of Hope for Cardiovascular Health

The [SELECT Trial] represents a significant step forward in the fight against cardiovascular disease in the context of obesity. The trial's rigorous design, employing a [Randomized, Double-Blind, Parallel-Group] approach, will provide robust evidence regarding the efficacy of [Semaglutide] in reducing cardiovascular risk. It's like discovering a hidden oasis in the desert of [Cardiovascular Disease], offering hope for a healthier future for those battling obesity and its associated cardiovascular risks.

The Potential of Semaglutide in Cardiovascular Health

This research explores the exciting potential of [Semaglutide], a [GLP-1 Receptor Agonist (RA)], in reducing cardiovascular risk in individuals with [Overweight or Obesity]. The trial's findings could revolutionize the management of cardiovascular disease in this high-risk population. It's like discovering a new source of water in the desert, bringing life and vitality to those who need it most.

Dr.Camel's Conclusion

The desert of [Cardiovascular Disease] can be a challenging place to navigate, especially for those struggling with obesity. The [SELECT Trial] offers a glimmer of hope, with [Semaglutide] holding the potential to reduce cardiovascular risk and improve the lives of millions. It's like finding a new oasis in the desert, offering a haven of health and well-being.

Date :
  1. Date Completed 2020-12-08
  2. Date Revised 2020-12-14
Further Info :

Pubmed ID

32916609

DOI: Digital Object Identifier

10.1016/j.ahj.2020.07.008

Related Literature

Article Analysis
・Effects of semaglutide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.